Device manufacturers track their own audit cycle with real discipline — the notified body's visits, the technical documentation review, the unannounced audit that can show up without warning. Far fewer track the compliance clock running in the other direction: the one the notified body itself is on. MDR Article 44 requires every notified body to face its own ongoing monitoring and periodic full re-assessment — and the certificate sitting in your technical file is only as durable as the designation behind it.
Two oversight layers, not one
Article 44 separates notified body oversight into two layers that run continuously, not sequentially. Article 44(4) keeps the designating authority running an annual assessment plan against the notified body — the ongoing layer, built to surface problems before they accumulate. Article 44(10) then requires a complete re-assessment on top of that, carried out with a joint assessment team rather than left to the designating authority alone. The two layers exist because annual monitoring and a full re-assessment catch different things: one tracks the notified body's day-to-day conduct, the other periodically re-examines its designation against the regulation's requirements from the ground up. Neither layer is run by the notified body on itself — both are run on the notified body, by the authority that designated it.
Why the re-assessment cycle got longer, not shorter
The instinct is to read a longer re-assessment interval as loosened oversight. That is not what Commission Delegated Regulation (EU) 2023/502 did. The original Article 44(10) called for a complete re-assessment three years after a notified body's initial notification, and every four years after that. The 2023 amendment, in force since March 11, 2023, moved both intervals to five years — explicitly because the annual monitoring under Article 44(4) was already running continuously, and because the number and capacity of notified bodies was still constrained during the MDR and IVDR transition. The change traded frequency of the heaviest check for reliance on the lighter, continuous one. It did not remove either layer, and a designating authority can still order a re-assessment earlier than the five-year mark if its own annual monitoring findings call for it.
A five-year re-assessment cycle is not five years of silence. It is five years in which the annual monitoring layer is doing the watching. Reading the 2023/502 amendment correctly
What this means for the manufacturer holding the certificate
Your CE marking strategy rests on a designation that is not static. A notified body's scope, standing, or designation can change as a result of this oversight — and MDR guidance treats the downstream consequences for in-force certificates as dependent on the specific scope and nature of any restriction, not as an automatic, uniform outcome. That is exactly the kind of exposure that belongs in planning rather than in a crisis call. Know which certificates sit with which notified body and which of your device codes fall inside its current designation scope — the same discipline that matters when checking whether a designation actually covers your classification codes in the first place. In an acquisition or licensing context, this belongs inside M&A due diligence and any regulatory gap assessment as a named question, not an assumption that a CE mark in hand settles the matter.
- Map certificates to designation scope. Confirm exactly which device codes your notified body's current designation covers.
- Watch the public designation record. NANDO reflects designation status and scope; check it on a schedule, not only when a question comes up.
- Price contingency into the timeline. Understand realistically what re-designation elsewhere would cost before you need to find out under pressure.
- Make it a diligence question. In any acquisition, licensing, or partnership involving EU devices, ask directly about notified body designation status and pending findings.
None of this changes what your own quality system has to do. It changes what you should be watching outside it. A certificate is only as durable as the designation that issued it, and that designation is on a clock you did not set and do not control — which is exactly the reason to know where it stands.
Frequently asked questions
What does MDR Article 44 require?
Article 44 requires the authority responsible for a notified body to run ongoing annual monitoring and assessment activities against that notified body under Article 44(4), plus a complete re-assessment on a fixed cycle under Article 44(10), carried out with a joint assessment team. It is the oversight mechanism that keeps a notified body's designation current — separate from any audit that notified body runs on your organization.
How often is a notified body fully re-assessed under MDR?
Originally, Article 44(10) required a complete re-assessment three years after a notified body's initial notification and every four years after that. Commission Delegated Regulation (EU) 2023/502, in force since March 11, 2023, extended both intervals to five years, citing the continuous annual monitoring already required under Article 44(4) and the limited capacity of notified bodies during the MDR/IVDR transition. A designating authority can still order an earlier re-assessment if its annual monitoring findings justify one.
What happens to my certificates if my notified body's designation is restricted?
The consequences depend on the scope and nature of the restriction, and MDR guidance treats this as a case-by-case determination rather than an automatic outcome. Treat the possibility as a planning question, not a remote scenario: know which of your certificates sit with which notified body, and confirm directly with your notified body and the relevant authority what a scope change would mean before you need the answer under pressure.
Sources & further reading
- European Commission. Commission Delegated Regulation (EU) 2023/502 of 1 December 2022 amending Regulation (EU) 2017/745 as regards the frequency of the complete re-assessment of notified bodies. eur-lex.europa.eu
- European Union. Regulation (EU) 2017/745 on medical devices, Article 44 (Monitoring and re-assessment of notified bodies). eur-lex.europa.eu
- European Commission. What a notified body is and what it does. health.ec.europa.eu
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current MDR Article 44 requirements and your notified body's designation status with the European Commission, NANDO, or qualified counsel before acting.